| An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic K Degeling, NN Baxter, J Emery, MA Jenkins, F Franchini, P Gibbs, ... Asia‐Pacific Journal of Clinical Oncology 17 (4), 359-367, 2021 | 99 | 2021 |
| Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late MJ IJzerman, J de Boer, A Azad, K Degeling, J Geoghegan, C Hewitt, ... Diagnostics 11 (1), 103, 2021 | 43 | 2021 |
| A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models K Degeling, H Koffijberg, MJ IJzerman Expert review of pharmacoeconomics & outcomes research 17 (1), 17-25, 2017 | 41 | 2017 |
| Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of … K Degeling, MD Franken, AM May, MGH van Oijen, M Koopman, ... Cancer epidemiology 57, 60-67, 2018 | 28 | 2018 |
| Impact van de eerste COVID-19 golf op de reguliere zorg en gezondheid: Inventarisatie van de omvang van het probleem en eerste schatting van gezondheidseffecten A Van Giessen, A De Wit, C Van den Brink, K Degeling, C Deuning, ... Rijksinstituut voor Volksgezondheid en Milieu RIVM, 2020 | 25 | 2020 |
| Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models K Degeling, MJ IJzerman, M Koopman, H Koffijberg BMC medical research methodology 17, 1-12, 2017 | 22 | 2017 |
| Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer YH To, K Degeling, S Kosmider, R Wong, M Lee, C Dunn, G Gard, A Jalali, ... Pharmacoeconomics 39 (8), 953-964, 2021 | 18 | 2021 |
| A scoping review of metamodeling applications and opportunities for advanced health economic analyses K Degeling, MJ IJzerman, H Koffijberg Expert review of pharmacoeconomics & outcomes research 19 (2), 181-187, 2019 | 17 | 2019 |
| Comparing strategies for modeling competing risks in discrete-event simulations: a simulation study and illustration in colorectal cancer K Degeling, H Koffijberg, MD Franken, M Koopman, MJ IJzerman Medical decision making 39 (1), 57-73, 2019 | 17 | 2019 |
| Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation CM Behr, H Koffijberg, K Degeling, R Vliegenthart, MJ IJzerman European radiology 32 (5), 3067-3075, 2022 | 14 | 2022 |
| Comparison of timed automata with discrete event simulation for modeling of biomarker-based treatment decisions: an illustration for metastatic castration-resistant prostate cancer K Degeling, S Schivo, N Mehra, H Koffijberg, R Langerak, JS de Bono, ... Value in health 20 (10), 1411-1419, 2017 | 13 | 2017 |
| Health economic models for metastatic colorectal cancer: a methodological review K Degeling, M Vu, H Koffijberg, HL Wong, M Koopman, P Gibbs, ... Pharmacoeconomics 38 (7), 683-713, 2020 | 11 | 2020 |
| Introduction to metamodeling for reducing computational burden of advanced analyses with health economic models: a structured overview of metamodeling methods in a 6-step … K Degeling, MJ IJzerman, MS Lavieri, M Strong, H Koffijberg Medical Decision Making 40 (3), 348-363, 2020 | 10 | 2020 |
| Evaluating the resource implications of different service delivery models for offering additional genomic findings M Vu, K Degeling, M Martyn, E Lynch, B Chong, C Gaff, MJ IJzerman Genetics in Medicine 23 (4), 606-613, 2021 | 7 | 2021 |
| Lifetime health and economic outcomes of active surveillance, radical prostatectomy, and radiotherapy for favorable-risk localized prostate cancer K Degeling, NM Corcoran, A Pereira-Salgado, AA Hamid, S Siva, ... Value in Health 24 (12), 1737-1745, 2021 | 6 | 2021 |
| Using metamodeling to identify the optimal strategy for colorectal cancer screening H Koffijberg, K Degeling, MJ IJzerman, VMH Coupé, MJE Greuter Value in health 24 (2), 206-215, 2021 | 5 | 2021 |
| Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model MD Franken, A de Hond, K Degeling, CJA Punt, M Koopman, ... Health and Quality of Life Outcomes 18, 1-13, 2020 | 5 | 2020 |
| Simulating progression-free and overall survival for first-line doublet chemotherapy with or without bevacizumab in metastatic colorectal cancer patients based on real-world … K Degeling, HL Wong, H Koffijberg, A Jalali, J Shapiro, S Kosmider, ... Pharmacoeconomics 38 (11), 1263-1275, 2020 | 4 | 2020 |
| Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, ... European Journal of Haematology 108 (6), 469-485, 2022 | 3 | 2022 |
| Cell-free DNA at diagnosis for stage IV non-small cell lung cancer: Costs, time to diagnosis and clinical relevance SN Koole, DCL Vessies, MMF Schuurbiers, A Kramer, RD Schouten, ... Cancers 14 (7), 1783, 2022 | 3 | 2022 |
